A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Duloxetine (Cymbalta)

Duloxetine delayed-release capsules is indicated for the treatment of: Major depressive disorder in adults Generalized anxiety disorder in adults and pediatric patients 7 years of age and older Dia....

First FDA approval2004-08-24
Generic availableYes · 16 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$496.0M in CY2024 Part D spend19.8M claims · 5.0M beneficiaries · 329 plans surveyed

Lowest NADAC
$0.085/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.085
Across all dosage forms in distribution.
Highest NADAC
$0.085
Range is tight.
Plans with PA
475 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Duloxetine used for?

Duloxetine delayed-release capsules is indicated for the treatment of: Major depressive disorder in adults Generalized anxiety disorder in adults and pediatric patients 7 years of age and older Dia....

Is there a generic for Duloxetine?

Yes. 52 ANDAs filed at FDA, 16 generic manufacturers currently shipping.

How much does my plan pay for Duloxetine?

Across 329 Part D plans, Duloxetine averages $0.085/unit (NADAC). Lowest available: $0.085/unit. Highest in distribution: $0.085/unit.

Is Duloxetine on the FDA shortage list?

No. Duloxetine is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)1 alternative in D1
01
Venlafaxine
Brand: Effexor
$0.069Lowest NADAC
27Generic mfrs
$240.4MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.